Amarin Corporation PLC Announces Enrollment of the REDUCE-IT Cardiovascular Outcomes Study Surpasses 6,000 Patients

Published: Sep 25, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the number of patients enrolled in the company's REDUCE-IT cardiovascular outcomes study of Vascepa® (icosapent ethyl) capsules has surpassed 6,000.

Help employers find you! Check out all the jobs and post your resume.

Back to news